Oxurion NV (formerly known as ThromboGenics NV), a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye, announced today the appointment of Adrienne Graves, Ph.D., to its board of directors. Dr. Graves will replace Paul Howes, who has been a board member since 2014.
Next 9th European Biotechnology Science & Industry Guide 2019!
Sponsored PublicationsIn March, the 9th edition of the "European Biotechnology Science & Industry Guide" will be published and distributed at BIO Europe Spring conference 2019 in Vienna. The B2B handbook presents companies and institutions in the fields of Biotech, Biopharma, BioServices and BioManufacturing an ideal medium with which new customers and investors can find you. The previous edition can be found here.
Argenx antibody kills AML
Latest NewsSanofi and Denali Therapeutics ink €1.125bn deal in neurology/inflammation
Latest NewsSanofi has acquired the global commercialisation rights for two preclinical programmes from Denali Therapeutics.
Adrienne Graves joins Oxurion’s Board
AppointmentsOxurion NV (formerly known as ThromboGenics NV), a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye, announced today the appointment of Adrienne Graves, Ph.D., to its board of directors. Dr. Graves will replace Paul Howes, who has been a board member since 2014.
ProQR in licence deal with Ionis Pharmaceuticals
Latest NewsFully human antibodies for advanced immunotherapies
BackgroundAnswering the increasing demand for novel fully human antibodies in immunotherapy, German biotech pioneer YUMAB GmbH accelerates drug discovery and development with a comprehensive and versatile technology platform.
Newron bags €40m EIB loan
Latest NewsThe EIB has agreed to support Italian CNS drug developer Newron Pharmaceuticals with up to €40m to support the development of the company’s late-stage pipeline.
TES Pharma presents new treatment approach towards AKI and NALFD
Latest NewsTES Pharma has presented a novel treatment approach for acute kidney injury and non-alcoholic fatty liver disease in Nature.
Asthma needs to be targeted more specifically
BackgroundUp to now, researchers believed that lung remodeling follows an autoimmune inflammation triggered by components of the extracellular matrix. In August, British scientists provided a more accurate view of the processes in the lung tissue, opening up a way to optimise failed mid-stage clinical candidates.
MEPs vote for ban of single-use plastics
Latest NewsThe European Parliament has approved measures that could lead to a ban of the top 10 single use plastic products that contribute to marine littering by 2021.